Oxfam is closely watching the outcome of Novartis’ endless and highly
damaging challenge to Section 3(d) of India’s Patent Act. We are profoundly disappointed that Novartis has continued to pursue legal action against the Indian Government. Five years ago, hundreds of thousands of people called upon Novartis to drop its legal challenge against the Indian. Today, over 2 billion people still lack regular access to affordable medicines, and yet Novartis has persisted. Oxfam is seriously concerned that if Novartis succeeds, it will lead to long term and profound changes in India’s patent system that will undermine generic competition and access to affordable,low-cost medicines.
- Lawmaker: Costly hepatitis C drug “a slap in the face to the veterans”
- Why is Gilead charging VA $40,000 for drug?
- UN Expert Urges TPP Countries Not to Sign the TPP Without Committing to Human Rights and Development
- India-EU FTA talks’ revival likely to be delayed
- President of Ukraine submits bill to parliament on changes to TRIPS agreement as for compulsory licensing mechanisms